Navigation Links
Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
Date:6/3/2008

percent; no patient achieved an objective response. The median PFS was 2.3 months. Three patients had a >6 month PFS. The disease control and median PFS are similar to results achieved in this patient population for approved agents (panitumumab or cetuximab monotherapy).

Safety data were qualitatively similar to that of irinotecan and a fluoropyrimidine with neutropenia, diarrhea, nausea, vomiting and fluid loss events (dehydration and hypokalemia) being the most common. The 210 unit/m2 dose produced more toxicities than seen in the CPX-1 Phase 1 clinical trial, resulting in only 40 percent of patients receiving >80 percent of the planned dose intensity. Treatment will be initiated at a lower dose in future studies.

"The efficacy results in this study are very encouraging, particularly compared to historical data," said Arthur Louie, M.D., chief medical officer of Celator. "These data support that drug ratios may play an important role when combining drugs to treat patients. This study shows that well established drugs with proven activity may offer greater clinical benefit when a synergistic ratio is identified and the individual drugs are locked into a drug delivery vehicle able to deliver and maintain the desired ratio in patients. Our goal is to substantially improve clinical outcomes by using our proprietary CombiPlex(TM) technology."

About Celator

Celator Pharmaceuticals, Inc., is a privately held pharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company's drug ratio technology platform, represents a revolutionary new approach that identifies a ratio of drugs that will deliver a synergistic benefit, locks the desired ratio in a drug delivery vehicle and maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a Phase 2 trial in patients with colorect
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
2. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
5. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
6. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
9. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
10. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
11. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
(Date:1/23/2015)... 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... adsorber to reduce deadly inflammation in critically-ill and ... net of transaction costs, in non-dilutive funding as ... Certificate Transfer Program sponsored by the New Jersey ...
(Date:1/23/2015)... BOSTON , January 23, 2015 ... development company, is delighted to announce that the Malcolm ... Miles Congreve (Vice President of Chemistry), Fiona ... Weir (Chief Executive Officer and co-founder) for the seminal ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... Nov. 7, 2011 Delcath Systems (NASDAQ: ... 2011 third quarter ended September 30, 2011.  Highlights for ... Research & Development:  Accelerated development of Generation ... has demonstrated significantly higher filtration efficiency of melphalan in ...
... Calif., Nov. 7, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, ... December 10-13, 2011, at the San Diego Convention Center ... being presented at ASH demonstrate carfilzomib,s potential activity along ...
Cached Medicine Technology:Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 2Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 3Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 4Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 5Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 6Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 7Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 8Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting 2Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting 3Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting 4Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting 5Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting 6
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
(Date:1/22/2015)... Weddingshe.com has added many trendy Champagne wedding dresses ... in the past three years. Today, the business announces a ... to the sales manager of the company, this is on ... This point can be reflected on the discounted wedding dresses ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store ... announces its latest collection of wedding dresses , and ... issue is the wedding dress on your big day; the ... life. Every bride wants to find the most suitable wedding ...
(Date:1/22/2015)... 2015 Step into a macabre world ... Museum of Virginia. Wicked Plants, the Museum’s latest featured ... 75 poisonous, carnivorous and diabolical plants inside of a ... uncover the biochemical, physical and neurological processes between botanicals ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... Players for the NFL,s,Chicago Bears will visit hospitalized ... Chicago VA medical center, as part of the Disabled,American ... McKie and running back Adrian Peterson are,scheduled to visit ... serving,our nation by signing autographs, presenting patients with souvenirs ...
... Health System are testing if vitamins A, C ... ANN ARBOR, Mich., Nov. 10 About ... from troops returning from war to,students with music ... hearing loss., The rising trend is something ...
... Recently issued study that found retail pharmacy workers are ... airborne pharmaceutical agents needs further review -, ... a statement today regarding serious concerns about efforts,by McKesson/Parata ... workers face when they work in pharmacies using air,pressure ...
... in aftermath of earthquake, WASHINGTON, Nov. 10 ... the People,s Republic of China in providing,measles vaccines ... control activities and strengthening the delivery of routine,immunization ... Sichuan --,areas severely impacted by the 8.0 magnitude ...
... Modern Warfare Fight For,Faster Benefit Decisions And Interim ... two groups,representing thousands of American veterans, Vietnam Veterans ... announced that they have filed,a lawsuit against the ... filed in the United States District Court for ...
... Tomorrow,s Health Care Heroes, HARRISBURG, Pa., Nov. ... working to build tomorrow,s health care,workforce by showcasing ... Careers Week., "This special week helps put ... paths that will benefit millions of,Pennsylvanians," said Governor ...
Cached Medicine News:Health News:Can Vitamins and Minerals Prevent Hearing Loss? 2Health News:Can Vitamins and Minerals Prevent Hearing Loss? 3Health News:Can Vitamins and Minerals Prevent Hearing Loss? 4Health News:Scientist Warns Industry Not to Ignore Potential Health Threat to Pharmacy Workers 2Health News:Scientist Warns Industry Not to Ignore Potential Health Threat to Pharmacy Workers 3Health News:Measles Initiative Supports Disease Prevention for Children in China's Earthquake Zone 2Health News:Measles Initiative Supports Disease Prevention for Children in China's Earthquake Zone 3Health News:Historic Lawsuit Challenges Unacceptable Delays in Delivering Benefits to America's Veterans by Department of Veterans Affairs 2Health News:Historic Lawsuit Challenges Unacceptable Delays in Delivering Benefits to America's Veterans by Department of Veterans Affairs 3Health News:Historic Lawsuit Challenges Unacceptable Delays in Delivering Benefits to America's Veterans by Department of Veterans Affairs 4Health News:Governor Rendell Shines Health Careers Week Spotlight on 8 In-Demand Occupations 2Health News:Governor Rendell Shines Health Careers Week Spotlight on 8 In-Demand Occupations 3
Our largest silicone tire with concave inner surface. Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Massive breaks covering large areas. Outside diameter 31.7 mm....
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (240 style). Indications: Wide scleral bed. Outside diameter 31.7 mm....
Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
2.5 mm x 0.6 mm. Overall length: 122 mm, 4.8 inches....
Medicine Products: